Full-Time

Senior Manager

Global Medical Information

Deadline 9/17/26
Alexion

Alexion

5,001-10,000 employees

Global biopharmaceuticals focusing on rare diseases

Compensation Overview

CA$101.6k - CA$133.4k/yr

Mississauga, ON, Canada

Hybrid

At least three days per week in the office; approximately 20% travel to domestic and international meetings or conferences.

Master's, PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Data Analysis

Get referred to Alexion

See people who can refer or advise you

Requirements
  • An advanced scientific degree in pharmacy (PharmD) or a related science (PhD, MD, or MSc), with at least 3 years of medical information or medical communications experience in the pharmaceutical or biotech industry, or completion of a PharmD post-doctoral fellowship in the pharmaceutical or biotech industry.
  • At least 1 year of relevant experience reviewing and approving local or regional promotional and/or non-promotional materials.
  • Proven success negotiating with and influencing partners.
  • Understanding of drug development, United States Food and Drug Administration and global regulations, and reporting requirements for pharmacovigilance events and product quality concerns.
  • Understanding of the process for developing medical information response documents using regulatory labels, published medical literature, clinical study reports, posters, and abstracts.
  • Working knowledge of artificial intelligence tools for Global Medical Information and Medical Review, including applying artificial intelligence to literature review, content development, and summarization, and evaluating outputs for scientific accuracy, compliance, confidentiality, and adherence to company policies.
  • Strong written and verbal communication skills.
  • Proficiency in literature-searching skills.
  • Proficiency with Microsoft Office Suite.
  • Ability to pay attention to detail.
  • Self-motivation to work toward results.
  • Strong organizational, time-management, and prioritization skills.
  • Ability to travel to domestic and international meetings or conferences approximately 20% of the time.
  • Ability to work in an office environment, use a computer, communicate through phone, video, and electronic messaging, perform problem solving and analysis, collaborate with others, and maintain general availability during standard business hours.
Responsibilities
  • Develop and maintain current, broad, and in-depth knowledge of pathophysiology, pharmacotherapy, and clinical outcomes associated with assigned products and disease states.
  • Deliver high-quality, balanced, and timely written or verbal medical and scientific information in response to unsolicited inquiries from health care professionals and consumers.
  • Research appropriate data and information sources to provide quick, accurate, and thorough responses.
  • Lead the research, outlining, composition, review, and ongoing maintenance of standard and custom medical information responses in various formats.
  • Provide direction to the third-party contact center regarding workflow procedures and standards, inquiries requiring escalation or customization, corrections from quality-control or case-review activities, and applicable new-hire or ongoing therapeutic-area and product training.
  • Proactively distribute important product and medical information to internal partners in support of product changes, safety issues, and other significant events.
  • Support preparation for and participation in medical information booth activities at professional scientific meetings and medical congresses.
  • Support the generation of therapeutic-area metrics and analytics and maintain an in-depth understanding of historic inquiry trends and insights.
  • Maintain current clinical data and knowledge-management systems or repositories.
  • Apply and comply with applicable ethical, legal, and regulatory standards for unsolicited information requests, on-label and off-label inquiries, and product promotion.
  • Support the creation and delivery of presentations to internal colleagues, including sharing inquiry metrics and customer insights and training commercial and medical field teams on procedures and medical-booth activities.
  • Create content for Medical Affairs when applicable and assist with reviewing and fact-checking data points and assessing the appropriateness of references cited in materials submitted to Promotional and Medical Review Committees.
  • Represent Medical comments in Promotional and Medical Review Committees when applicable.
  • Report product-quality complaints and adverse events to Quality Assurance or Drug Safety in accordance with corporate policies when applicable.
  • Support operational initiatives such as developing and maintaining standard operating procedures and training modules, enhancing databases and systems, and overseeing vendors when applicable.
  • Support broader Medical Communications activities, including Medical Education and Scientific Communication, when applicable.
  • Support the medical review and approval of promotional and non-promotional materials when applicable.
Desired Qualifications
  • Experience providing medical information or medical communications support within a global function.
  • At least 4 years of medical information, medical review, or medical communications experience in the pharmaceutical or biotech industry.
  • Prior experience with medical information systems or databases such as IRMS, or promotional and medical review systems such as Veeva PromoMats.
  • Experience creating Medical Affairs content.
  • Ability to learn new software and applications quickly.
  • Training or experience in assigned therapeutic areas or rare disease.
  • Experience working on product launches.
  • Completion of a PharmD post-doctoral fellowship in the pharmaceutical or biotech industry.

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Relocation Assistance

Employee Referral Bonus

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old